MD Anderson Collaborates with Advalytix to Study Breast Cancer Cells | GenomeWeb
NEW YORK (GenomeWeb News) – The University of Texas MD Anderson Cancer Center will use multiplex gene expression technology from Olympus subsidiary Advalytix to develop molecular diagnostic technologies for personalizing cancer treatment and detection, the company said this week.
 
Under a collaborative study, the partners will use Advalytix’s AmpliGrid molecular analysis platform to characterize circulating tumor cells in breast cancer patients.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.